Literature DB >> 21338189

Cancer incidence and mortality in Mongolia - National Registry Data.

Tuvshingerel Sandagdorj1, Erdenechimeg Sanjaajamts, Undarmaa Tudev, Dondov Oyunchimeg, Chimedsuren Ochir, David Roder.   

Abstract

BACKGROUND: The National Cancer Registry of Mongolia began as a hospital-based registry in the early 1960s but then evolved to have a population-wide role. The Registry provides the only cancer data available from Mongolia for international comparison. The descriptive data presented in this report are the first to be submitted on cancer incidence in Mongolia to a peer-reviewed journal. The purpose was to describe cancer incidence and mortality for all invasive cancers collectively, individual primary sites, and particularly leading sites, and consider cancer control opportunities.
METHODS: This study includes data on new cancer cases registered in Mongolia in 2003-2007. Incidence and mortality rates were calculated as mean annual numbers per 100,000 residents. Age-standardized incidence (ASR) and age-standardized mortality (ASMR) rates were calculated from age-specific rates by weighting directly to the World Population standard.
RESULTS: Between 2003 and 2007, 17,271 new cases of invasive cancer were recorded (52.2% in males, 47.7% in females). The five leading primary sites in males were liver, stomach, lung, esophagus, and colon/rectum; whereas in females they were liver, cervix, stomach, esophagus and breast. ASRs were lower in females than males for cancers of the liver at 63.0 and 99.1 per 100,000 respectively; cancers of the stomach at 19.1 and 42.1 per 100,000 respectively; and cancers of the lung at 8.3 and 33.2 per 100,000 respectively. Liver cancer was the most common cause of death in each gender, the ASMR being lower for females than males at 60.6 compared with 94.8 per 100,000. In females the next most common sites of cancer death were the stomach and esophagus, whereas in males, they were the stomach and lung. DISCUSSION: Available data indicate that ASRs of all cancers collectively have increased over the last 20 years. Rates are highest for liver cancer, at about four times the world average. The most common cancers are those with a primary site of liver, stomach and esophagus, for which cases fatality rates are high in all populations. Emphasis is given in the National Cancer Control Program (NCCP) to limiting treatment for these and other high-fatality cancers to the small sub-set of potentially curable cases, while focusing on palliative care and patient support for the remainder. Meanwhile opportunities are being pursued to prevent liver cancer through hepatitis B vaccination and lung cancer through tobacco control, and to reduce cervical cancer mortality by finding lesions at a pre-malignant or early invasive stage.

Entities:  

Mesh:

Year:  2010        PMID: 21338189

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  14 in total

1.  A physician order category-based clinical guideline comparison system.

Authors:  Hwan-Jeu Yu; Chia-Ping Shen; Sarangerel Dorjgochoo; Chi-Huang Chen; Jin-Ming Wu; Mei-Shu Lai; Ching-Ting Tan; Chinburen Jigjidsuren; Erdenebaatar Altangerel; Hung-Chang Lee; Chih-Wen Hsueh; Yufang Chung; Feipei Lai
Journal:  J Med Syst       Date:  2012-03-30       Impact factor: 4.460

2.  Association between MDM2-SNP309 and p53R72P polymorphisms and the risk of bladder cancer in the Mongolian population.

Authors:  Shiirevnyamba Avirmed; Bo-Shen Wang; Baasansuren Selenge; Amarsaikhan Sanjaajamts; Batmunkh Ganbat; Ulziisaikhan Erdenebileg; Myagmarsuren Purevsuren; Sarantsetseg Jigjidsuren; Munkhbat Batmunkh; Yi-Jang Lee
Journal:  Mol Clin Oncol       Date:  2017-07-13

3.  Breast cancer incidence in Mongolia.

Authors:  Rebecca Troisi; Dalkhjav Altantsetseg; Ganmaa Davaasambuu; Janet Rich-Edwards; Dambadarjaa Davaalkham; Steinar Tretli; Robert N Hoover; A Lindsay Frazier
Journal:  Cancer Causes Control       Date:  2012-04-29       Impact factor: 2.506

4.  Gastric mucosa in Mongolian and Japanese patients with gastric cancer and Helicobacter pylori infection.

Authors:  Takeshi Matsuhisa; Yoshio Yamaoka; Tomohisa Uchida; Davaadorj Duger; Battulga Adiyasuren; Oyuntsetseg Khasag; Tserentogtokh Tegshee; Byambajav Tsogt-Ochir
Journal:  World J Gastroenterol       Date:  2015-07-21       Impact factor: 5.742

Review 5.  Prostate cancer in Asian men.

Authors:  Kazuto Ito
Journal:  Nat Rev Urol       Date:  2014-03-04       Impact factor: 14.432

Review 6.  Cancer control programs in East Asia: evidence from the international literature.

Authors:  Malcolm A Moore
Journal:  J Prev Med Public Health       Date:  2014-07-31

7.  Screening and management of viral hepatitis and hepatocellular carcinoma in Mongolia: results from a survey of Mongolian physicians from all major provinces of Mongolia.

Authors:  Yoona A Kim; Jacqueline Estevez; An Le; Dennis Israelski; Oidov Baatarkhuu; Tserenchimed Sarantuya; Sonom Narantsetseg; Pagbajabyn Nymadawa; Richard H Le; Man-Fung Yuen; Geoffrey Dusheiko; Mario Rizzetto; Mindie H Nguyen
Journal:  BMJ Open Gastroenterol       Date:  2016-11-10

8.  Open-label Phase II clinical trial in 75 patients with advanced hepatocellular carcinoma receiving daily dose of tableted liver cancer vaccine, hepcortespenlisimut-L.

Authors:  Marina G Tarakanovskaya; Jigjidsuren Chinburen; Purev Batchuluun; Chogsom Munkhzaya; Genden Purevsuren; Dorjiin Dandii; Tsogkhuu Hulan; Dandii Oyungerel; Galyna A Kutsyna; Alan A Reid; Vika Borisova; Allen I Bain; Vichai Jirathitikal; Aldar S Bourinbaiar
Journal:  J Hepatocell Carcinoma       Date:  2017-04-12

Review 9.  Breast cancer in Mongolia: an increasingly important health policy issue.

Authors:  Delgermaa Demchig; Claudia Mello-Thoms; Patrick C Brennan
Journal:  Breast Cancer (Dove Med Press)       Date:  2017-01-20

Review 10.  Cervical Cancer Prevalence, Incidence and Mortality in Lowzzm321990and Middle Income Countries: A Systematic Review

Authors:  Aamod Dhoj Shrestha; Dinesh Neupane; Peter Vedsted; Per Kallestrup
Journal:  Asian Pac J Cancer Prev       Date:  2018-02-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.